Eli Lilly Bets Big on Dicerna’s Gene-Silencing Technology
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)
Published: 3 Nov-2018
DOI: 10.3833/pdr.v2018.i11.2367 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Eli Lilly has partnered with Dicerna to use the latter’s GalXC™ platform to discover and develop RNA interference therapies for more than 10 targets in a deal potentially worth over US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS